Nanoparticles News and Research

RSS

New injectable material delivers drug therapies and sensor technology to targeted areas in human body

A new injectable material designed to deliver drug therapies and sensor technology to targeted areas within the human body is being developed by a Texas A&M University biomedical engineer who says the system can lock its payload in place and control how it is released.

23 Jan 2014

Chinese and American researchers introduce new approach to gene therapy

Resistance of tumor cells toward multiple cytostatic drugs is a serious problem in cancer treatment. In the journal Angewandte Chemie, a team of Chinese and American researchers has now introduced a new approach to gene therapy that could counter this problem: The gene that codes for resistance is “silenced” through the use of an ingenious nanocomplex.

22 Jan 2014

Damon Runyon Cancer Research Foundation awards $2.25M to six innovative young scientists

The Damon Runyon Cancer Research Foundation announced that six scientists with novel approaches to fighting cancer have been named 2014 recipients of the Damon Runyon-Rachleff Innovation Award. The grant of $450,000 over three years is awarded each year to early career scientists whose projects have the potential to significantly impact the prevention, diagnosis and treatment of cancer.

21 Jan 2014

Breakthrough technology could provide new approach for treatment of chronic wounds

A team of researchers led by an NIBIB grantee at Vanderbilt University has created a biodegradable scaffold that enables sustained, local delivery of gene-silencing factors called siRNA to promote tissue regeneration. The team recently used the scaffold to successfully deliver siRNA to mice in order to locally silence a gene normally responsible for inhibiting blood vessel formation.

20 Jan 2014

Scientist receives grant to study biochemical fate of nanoemulsion-based food delivery systems in GI tract

Food scientist Hang Xiao of the University of Massachusetts Amherst recently received a four-year, $491,220 grant to study the biochemical fate of nanoemulsion-based food delivery systems in the gastrointestinal (GI) tract, hoping to re-shape them and enhance the absorption of beneficial food components encapsulated in delivery systems.

20 Jan 2014

Research findings could lead to life-saving treatments to fight tumor metastasis

A team of researchers from the Cleveland Clinic and Case Western Reserve School of Medicine have identified critical complex mechanisms involved in the metastasis of deadly "triple negative" breast cancers. These tumors are extremely difficult to treat, frequently return after remission, and are the most aggressive form of breast cancer in women. The discovery of this critical interaction of mechanisms could be used to develop new life saving treatments to kill metastatic tumors in TNBC.

17 Jan 2014

Researchers identify complex mechanisms involved in metastasis of deadly TNBC

17 Jan 2014

Research identifies new way for slow release drugs

Reservoirs of pharmaceuticals could be manufactured to bind specifically to infected tissue such as cancer cells for slow, concentrated delivery of drug treatments, according to new research published in ACS Macro Letters.

15 Jan 2014

New system allows us to power our devices long after sun goes down

Solar energy has long been used as a clean alternative to fossil fuels such as coal and oil, but it could only be harnessed during the day when the sun's rays were strongest. Now researchers led by Tom Meyer at the Energy Frontier Research Center at the University of North Carolina at Chapel Hill have built a system that converts the sun's energy not into electricity but hydrogen fuel and stores it for later use, allowing us to power our devices long after the sun goes down.

15 Jan 2014

Notre Dame, Loyola partner to provide direct support for revolutionary new cancer research

Two research powerhouses, Loyola University Chicago and the University of Notre Dame, are joining forces in a multidisciplinary cancer research collaboration.

8 Jan 2014

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that the European Commission has granted approval for ABRAXANE (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine for first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas, or metastatic pancreatic cancer.

7 Jan 2014

Cancer cells less likely to develop resistance when multiple drugs delivered simultaneously

Researchers have developed a technique for creating nanoparticles that carry two different cancer-killing drugs into the body and deliver those drugs to separate parts of the cancer cell where they will be most effective. The technique was developed by researchers at North Carolina State University and the University of North Carolina at Chapel Hill.

7 Jan 2014

Astellas, ClearPath announce strategic partnership to develop vaccine for infectious diseases

Astellas Pharma Inc. (Astellas) and ClearPath Development Company (ClearPath) announced today a strategic partnership to form a portfolio of development companies focused on vaccines targeting infectious diseases.

6 Jan 2014

Innovative therapy offers new hope to breast cancer patients

A novel breast-cancer therapy that partially reverses the cancerous state in cultured breast tumor cells and prevents cancer development in mice, could one day provide a new way to treat early stages of the disease without resorting to surgery, chemotherapy or radiation, a multi-institutional team led by researchers from the Wyss Institute of Biologically Inspired Engineering at Harvard University reported January 1 in Science Translational Medicine.

2 Jan 2014

New technique could help researchers unlock the secrets of respiratory syncytial virus

By the time they're two, most children have had respiratory syncytial virus and suffered symptoms no worse than a bad cold. But for some children, especially premature babies and those with underlying health conditions, RSV can lead to pneumonia and bronchitis - which can require hospitalization and have long-term consequences.

30 Dec 2013

Magnetic nanoparticles-based method uses saliva to screen DNA polymorphism in stroke patients

C677T polymorphism in the methylenetetrahydrofolate reductase (MTHFR) gene is a risk factor for stroke. Studies have report a higher C677T homozygosity frequency in Chinese than in Europeans. Usually, the detection of genetic diseases is rather complicated on a large scale owing to the invasive sampling and a cumbersome DNA extraction process.

27 Dec 2013

New research assesses nanomedicine-based approaches for treating cancer

As cancer maintains its standing as the second leading cause of death in the U.S., researchers have continued their quest for safer and more effective treatments. Among the most promising advances has been the rise of nanomedicine, the application of tiny materials and devices whose sizes are measured in the billionths of a meter to detect, diagnose and treat disease.

20 Dec 2013

Researchers construct "golden trap" capable of capturing molecules

The method's high sensitivity lies in the customized environment for the substance of interest. Dresden's Adrian Keller and his colleagues have constructed a type of "golden trap" capable of capturing the molecules and thereby enabling their detection.

16 Dec 2013

Researchers discover easy-to-use method for bonding gels and biological tissues

Researchers have discovered an efficient and easy-to-use method for bonding together gels and biological tissues. A team headed by Ludwik Leibler, involving researchers from the Laboratoire Matière Molle et Chimie (CNRS/ESPCI ParisTech) and the Laboratoire Physico-Chimie des Polymères et Milieux Dispersés (CNRS/ UPMC/ESPCI ParisTech), has succeeded in obtaining very strong adhesion between two gels by spreading on their surface a solution containing nanoparticles.

12 Dec 2013

Adocia gets development and commercialization rights in nanotechnology for drug delivery

Adocia, a biotechnology company specializing in the development of ‘best-in-class’ medicines from already approved therapeutic proteins, announces today the signature of an exclusive license agreement with the CNRS, the University Bordeaux I, the Institut Polytechnique de Bordeaux and Aquitaine Science Transfert.

9 Dec 2013